JP4209086B2 - 長期持続性抗新脈管形成ペプチド - Google Patents

長期持続性抗新脈管形成ペプチド Download PDF

Info

Publication number
JP4209086B2
JP4209086B2 JP2000619018A JP2000619018A JP4209086B2 JP 4209086 B2 JP4209086 B2 JP 4209086B2 JP 2000619018 A JP2000619018 A JP 2000619018A JP 2000619018 A JP2000619018 A JP 2000619018A JP 4209086 B2 JP4209086 B2 JP 4209086B2
Authority
JP
Japan
Prior art keywords
peptide
kringle
group
fmoc
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000619018A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003500341A5 (zh
JP2003500341A (ja
Inventor
ドミニク ピー． ブライドン，
ミケル ラサモエリソロ，
カレン シボーデュー，
シィカイ ヒュアン，
リチャード ビリビュー，
Original Assignee
コンジュケム バイオテクノロジーズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コンジュケム バイオテクノロジーズ インコーポレイテッド filed Critical コンジュケム バイオテクノロジーズ インコーポレイテッド
Publication of JP2003500341A publication Critical patent/JP2003500341A/ja
Publication of JP2003500341A5 publication Critical patent/JP2003500341A5/ja
Application granted granted Critical
Publication of JP4209086B2 publication Critical patent/JP4209086B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
JP2000619018A 1999-05-17 2000-05-17 長期持続性抗新脈管形成ペプチド Expired - Fee Related JP4209086B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13440699P 1999-05-17 1999-05-17
US60/134,406 1999-05-17
PCT/IB2000/000763 WO2000070665A2 (en) 1999-05-17 2000-05-17 Long lasting anti-angiogenic peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008008554A Division JP2008110986A (ja) 1999-05-17 2008-01-17 長期持続性抗新脈管形成ペプチド

Publications (3)

Publication Number Publication Date
JP2003500341A JP2003500341A (ja) 2003-01-07
JP2003500341A5 JP2003500341A5 (zh) 2006-01-05
JP4209086B2 true JP4209086B2 (ja) 2009-01-14

Family

ID=22463240

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2000619018A Expired - Fee Related JP4209086B2 (ja) 1999-05-17 2000-05-17 長期持続性抗新脈管形成ペプチド
JP2008008554A Withdrawn JP2008110986A (ja) 1999-05-17 2008-01-17 長期持続性抗新脈管形成ペプチド
JP2009023118A Withdrawn JP2009143941A (ja) 1999-05-17 2009-02-03 長期持続性抗新脈管形成ペプチド

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2008008554A Withdrawn JP2008110986A (ja) 1999-05-17 2008-01-17 長期持続性抗新脈管形成ペプチド
JP2009023118A Withdrawn JP2009143941A (ja) 1999-05-17 2009-02-03 長期持続性抗新脈管形成ペプチド

Country Status (9)

Country Link
EP (1) EP1171582A2 (zh)
JP (3) JP4209086B2 (zh)
CN (2) CN1698881A (zh)
AU (1) AU764103B2 (zh)
CA (1) CA2373252C (zh)
SM (1) SM200000031A (zh)
TW (1) TWI300414B (zh)
WO (1) WO2000070665A2 (zh)
ZA (2) ZA200106676B (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002239414A1 (en) * 2000-11-02 2002-05-27 Bristol-Myers Squibb Company Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors
DE60226702D1 (de) 2001-02-16 2008-07-03 Conjuchem Biotechnologies Inc Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
DE60229677D1 (de) 2001-05-31 2008-12-11 Conjuchem Biotechnologies Inc Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
CA2488348A1 (en) * 2002-07-31 2004-02-05 Conjuchem Inc. Long lasting natriuretic peptide derivatives
EA007918B1 (ru) * 2002-09-24 2007-02-27 Франтиэ Биотекнолоджиз Ко., Лтд. Пептидные производные-ингибиторы слияния при вич-инфекции
CN103897031A (zh) * 2012-12-25 2014-07-02 深圳先进技术研究院 化学修饰的胸腺五肽及其合成方法
CN104892725A (zh) * 2015-05-19 2015-09-09 广州诺威生物技术有限公司 一种萘乙酰胺新化合物
CN109503700A (zh) * 2017-09-14 2019-03-22 南京安吉生物科技有限公司 马来酰亚胺基团修饰的血管生成抑制剂hm-1及其应用
CN110372781B (zh) * 2019-07-29 2021-11-16 深圳佳肽生物科技有限公司 恩夫韦肽的制备方法和应用
CN117186187B (zh) * 2023-07-12 2024-05-31 中国医学科学院病原生物学研究所 一种抗呼吸道合胞病毒膜融合抑制剂及其药物用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0602290B1 (en) * 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
NZ330537A (en) * 1995-12-13 2001-06-29 Childrens Medical Center Kringle 5 rerion of plasminogen as an endothelial cell proliferation inhibitor
DE69733756T2 (de) * 1996-05-03 2006-06-01 Abbott Laboratories, Abbott Park Antiangiogenische peptiden, dafür kodierende polynukleotide und verfahren zur hemmung der angiogenesis
ES2173641T3 (es) * 1997-11-07 2002-10-16 Conjuchem Inc Composicion de derivados opiaceos para la fabricacion de medicamentos.
CA2628053A1 (en) * 1997-11-07 1999-05-20 Conjuchem Biotechnologies Inc. Affinity markers for human serum albumin
AU748496B2 (en) * 1998-03-23 2002-06-06 Conjuchem, Inc. Local delivery of long lasting therapeutic agents
GB9815505D0 (en) * 1998-07-16 1998-09-16 Adprotech Plc Polypeptide derivatives

Also Published As

Publication number Publication date
TW200524957A (en) 2005-08-01
WO2000070665A3 (en) 2001-04-19
AU4774800A (en) 2000-12-05
AU764103B2 (en) 2003-08-07
EP1171582A2 (en) 2002-01-16
ZA200106676B (en) 2002-07-19
CA2373252A1 (en) 2000-11-23
JP2003500341A (ja) 2003-01-07
JP2008110986A (ja) 2008-05-15
CN101289500A (zh) 2008-10-22
CA2373252C (en) 2007-08-07
TWI300414B (en) 2008-09-01
WO2000070665A2 (en) 2000-11-23
SM200000031B (it) 2001-11-21
JP2009143941A (ja) 2009-07-02
SM200000031A (it) 2001-11-21
ZA200109110B (en) 2002-06-13
CN1698881A (zh) 2005-11-23

Similar Documents

Publication Publication Date Title
US7741286B2 (en) Long lasting anti-angiogenic peptides
US7112567B2 (en) Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
US8080516B2 (en) Long lasting synthetic exendin-4 peptide conjugates
JP2008110986A (ja) 長期持続性抗新脈管形成ペプチド
AU2002233089A1 (en) Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
US7144854B1 (en) Long lasting anti-angiogenic peptides

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070717

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071016

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071023

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20071025

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071112

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071214

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071221

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080117

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080623

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080630

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080801

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080801

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20081014

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20081022

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111031

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121031

Year of fee payment: 4

LAPS Cancellation because of no payment of annual fees